Meeting Overview - The first extraordinary general meeting of shareholders for YunSai ZhiLian Co., Ltd. was held on November 13, 2025, in Shanghai [2] - The meeting was convened by the board of directors and chaired by the general manager, Jiang Xiaoyong, using a combination of on-site and online voting [2][3] Attendance and Voting - All five current directors attended the meeting, along with the company secretary and other senior management [3] - The meeting had no rejected resolutions, and the voting process complied with the Company Law and the company's articles of association [2][3] Resolutions Passed - The proposal to increase the daily related party transaction limit for 2025 was approved [3][4] - The proposal to supplement the board of directors was also discussed, with specific voting details not disclosed [3] Legal Verification - The meeting was witnessed by lawyers from Beijing Tongshang Law Firm, confirming that the meeting's procedures and results were legal and valid [4] Board of Directors Meeting - The 23rd meeting of the 12th board of directors was held on November 13, 2025, with all seven directors present [8] - The board elected Liu Shanqian as the chairman of the 12th board of directors, with a unanimous vote of 7 in favor [9] Committee Adjustments - The board approved adjustments to the members of its specialized committees, including the Strategic Committee, Audit and Compliance Committee, Nomination Committee, and Compensation and Assessment Committee [9][10][11][12]

Group 1 - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals [1][6] - The agenda includes the cancellation of the supervisory board, amendments to the articles of association, and the signing of a national agency agreement for the product "TY-9591" [1][16] - The meeting will allow shareholders to exercise their rights, including speaking, questioning, and voting [2][4] Group 2 - The company proposes to cancel the supervisory board and transfer its responsibilities to the audit committee of the board of directors, following the latest legal and regulatory requirements [7][8] - The amendments to the articles of association will also lower the threshold for temporary proposals from 3% to 1% of shares held by shareholders [7] - The company will seek to register these changes with the relevant authorities after shareholder approval [8] Group 3 - The company plans to increase the expected amount of daily related transactions for 2025, detailing specific amounts and categories of transactions [12][13] - The expected increase includes a rise in transactions with related parties, such as an increase from 2 billion to 2.5 billion for a specific supplier [13][14] - The company has reached a threshold of 30 million in related transactions over the past twelve months, necessitating shareholder approval for the new expected amounts [15][17] Group 4 - The company intends to sign a national agency agreement for the "TY-9591" product with Zhejiang Tongyuan Pharmaceutical Co., Ltd., with a milestone payment of 150 million [16][18] - This agreement is classified as a related party transaction, and the relationship with the related party will terminate in March 2026 [16][18] - The company has disclosed the details of this agreement in prior announcements to ensure transparency [17] Group 5 - The company is nominating Mr. Zhang Chunping as a non-independent director to fill a vacancy on the board [19][20] - This nomination follows the resignation of a previous non-independent director and aims to maintain the operational integrity of the board [19][20] - The board's nomination committee has reviewed Mr. Zhang's qualifications in accordance with relevant laws and regulations [20]